TB Alliance at the 2019 Union Conference
Join TB Alliance at the 50th Union World Conference on Lung Health in Hyderabad, India, taking place 30 October - 2 November 2019. Follow our live coverage on Twitter using @TBAlliance, #UnionConf and #BreakingResistance.
TB Alliance and partners will provide an update on treatment for highly drug-resistant forms of tuberculosis ahead of this year's 50th Union World Conference on Lung Health in Hyderabad.
Participants will share information about advances in tuberculosis research and drug development, as well as discuss the current status of introduction and uptake planning for a new TB therapy.
- Mel Spigelman, President and CEO, TB Alliance
- Sandeep Juneja, SVP Market Access, TB Alliance
- Rhea Lobo, TB survivor and Co-Chair, Bolo Didi
Followed by panel discussion moderated by Sanchita Sharma, Health and Science Editor, Hindustan Times, including:
- Lucica Ditiu, Executive Director of the Stop TB Partnership
- Yogan Pillay, Deputy Director General, Department of Health, South Africa
- Kuldeep Singh Sachdeva, Deputy Director General, Central TB Division Ministry of Health and Family Welfare, Government of India
- Anil Soni, Head of Global Infectious Diseases, Mylan
- Kitty van Weezenbeek, Executive Director, KNCV Tuberculosefonds
We hope you will plan to join us, and request that you register for the event here. Event registration opens at 14:00 and the event will begin at 14:30, followed by a reception.
14:30-16:00 | Avasa Hotel, Constellation Room
Thursday, October 31
TB Alliance Exhibit Booth
All day | Hyderabad Convention Centre, Booth C3303
Meet with TB Alliance to discuss the discovery, development and delivery of new, improved TB treatments for patients who need them and to learn more about our R&D pipeline. Find us at the Convention Centre – Booth number C3303! The booth will be open until 14:00 on Saturday, November 2.
All day | Hyderabad Convention Centre, Booth G5505
Join the #LouderThanTB campaign in the Community Connect exhibit area to watch #TBCourage stories of patients, survivors and those who have been impacted by the disease. The booth will showcase the new TB Digital Quilt where you can share your own #TBCourage story. The booth will be open until 14:00 on Saturday, November 2.
Oral Abstract Presentation: Fluoroquinolone susceptibility testing to accompany fluoroquinolone-containing universal regimens: the setting dependence of optimal Xpert XDR use
16:00-17:00 | Hyderabad Convention Centre, Hall 2
TB Alliance and partner, Johns Hopkins University, will present findings on a study evaluating rifampin (RIF)-free regimens that combine novel TB drugs with drugs to which nontrivial resistance already exists to treat both drug-susceptible and rifampin-resistant (RIF-R) TB.
Friday, November 1
Symposium: Nix-TB trial experience: safety reporting and recommendations for programmatic implementation of the regimen
10:30-10:45 | Hyderabad Convention Centre, Hall 3
Dr. Francesca Conradie will present findings from the Nix-TB clinical trial experience as part of a symposium reporting on progress in identifying short treatment regimens for MDR-TB.
Oral Abstract Presentation: Expected patient impact of the novel BPaMZ regimen depends upon implementation approach and rifampin-resistance epidemiology
16:00-17:00 | Hyderabad Convention Centre, MR 1.05 & 1.06
TB Alliance and partner, Johns Hopkins University, will present findings from a modeling study of the BPaMZ (bedaquiline, pretomanid, moxifloxacin, and pyrazinamide) regimen to fight TB, derived from a Markov state-transition model of 100,000 South African adults with rifampin-susceptible (RS) and rifampin-resistant (RR) TB undergoing diagnosis and treatment.
Saturday, November 2
Short Oral Abstract: Pretomanid susceptibility testing of Mycobacterium tuberculosis complex isolates using the BACTEC MGIT 960 system
14:00-15:30 | Hyderabad Convention Centre, Hall 6
TB Alliance's Juliano Timm will present findings from a study conducted to define protocols and quality control ranges for pretomanid drug susceptibility testing using the BACTEC MGIT 960 system, as well as to determine its critical concentration and epidemiological cut-off value.